Isolated gastrointestinal Langerhans cell histiocytosis in a 16‐month‐old child: A case report

Langerhans cell histiocytosis (LCH) is a rare disorder characterized by clonal proliferation of Langerhans cells, most often involving the skin or bone. Isolated gastrointestinal (GI) involvement is extremely uncommon in young children. We report a 16-month-old girl with a 1-month history of chronic vomiting, bloody diarrhea, and failure to thrive who was found to have GI-LCH without systemic involvement. She was started on standard LCH chemotherapy with a favorable clinical response. This case highlights the importance of considering LCH in infants/toddlers with unexplained GI symptoms and the utility of targeted molecular testing (e.g., BRAF mutation analysis) in guiding therapy.

Authors

Institutions

Publication Details

Journal
JPGN Reports
Published
2025-10-14
DOI
https://doi.org/10.1002/jpr3.70096
Primary Topic
Histiocytic Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Isolated gastrointestinal Langerhans cell histiocytosis in a 16‐month‐old child: A case report

Mohammed Al‐Masqari, Al‐Qasim Al‐Bahlani, Emad Saad, Laraib Touseeq
JPGN Reports
Histiocytic Disorders and Treatments
article

Isolated gastrointestinal Langerhans cell histiocytosis in a 16‐month‐old child: A case report

Mohammed Al‐Masqari, Al‐Qasim Al‐Bahlani, Emad Saad, Laraib Touseeq
article en

Abstract

Langerhans cell histiocytosis (LCH) is a rare disorder characterized by clonal proliferation of Langerhans cells, most often involving the skin or bone. Isolated gastrointestinal (GI) involvement is extremely uncommon in young children. We report a 16-month-old girl with a 1-month history of chronic vomiting, bloody diarrhea, and failure to thrive who was found to have GI-LCH without systemic involvement. She was started on standard LCH chemotherapy with a favorable clinical response. This case highlights the importance of considering LCH in infants/toddlers with unexplained GI symptoms and the utility of targeted molecular testing (e.g., BRAF mutation analysis) in guiding therapy.

JPGN ReportsVol. 7(1)
Royal Hospital (OM)
Openalex Percentile: Top 64%
Histiocytic Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.